




RealRate

PHARMACEUTICAL 2012

Vertex Pharmaceuticals INC MA
Rank 101 of 196



The relative strengths and weaknesses of Vertex Pharmaceuticals INC MA are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vertex Pharmaceuticals INC MA compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Vertex Pharmaceuticals INC MA is the variable Other Liabilities, reducing the Economic Capital Ratio by 75% points.

The company's Economic Capital Ratio, given in the ranking table, is 249%, being 15% points above the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	1,331,254
Cost of Goods Sold	0
Intangible Assets	30,992
Liabilities, Current	392,348
Liabilities, Non-Current	7,287
Other Assets	708,858
Other Compr. Net Income	0
Other Expenses	246,097
Other Liabilities	839,133
Other Net Income	-14,923
Other Revenues	1,410,626
Property and Equipment	133,176
Research and Development	707,706
Selling, General and Administrative Expense	400,721

Output Variable	Value in 1000 USD
Assets	2,204,280
Liabilities	1,238,768
Expenses	1,354,524
Revenues	1,410,626
Stockholders Equity	965,512
Net Income	41,179
Comprehensive Net Income	41,179
BaseVar	3,111,560
ECR before LimitedLiability	125%
Economic Capital Ratio	249%